Super response to liraglutide in people with obesity: A case report and literature review

Sonsoles Gutiérrez Medina,Elena Sánchez Campayo,Sonsoles Guadalix,Javier Escalada
DOI: https://doi.org/10.1016/j.endien.2024.11.012
Abstract:GLP1 receptor agonists (GLP1-RAs) are currently the most widely used pharmacological option to treat obesity. However, considerable heterogeneity in weight loss response has been observed with different anti-obesity drugs and response predictors to these drugs still remain ambiguous. Furthermore, very few published data have been available on cases of high-responders to treatment with GLP1-RAs. In this article, we present the case of a patient with grade 4 obesity (initial body mass index, 50.2kg/m2) with associated mechanical and metabolic complications who achieved an initial weight loss of 40% at 1 year with hygienic-dietary measures and drug treatment with liraglutide. We also review the available literature on factors potentially contributing to variations in weight loss with GLP1-RAs in general and liraglutide, in particular.
What problem does this paper attempt to address?